Zai Lab Announces Participation in Investor Conference in January 2025

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2025:

43rd Annual J.P. Morgan Healthcare Conference
Presentation: Tuesday, January 14, 2025, 1:30 p.m. PST
Location: San Francisco

A live webcast of the presentation will be available on the Investor Relations page of Zai Lab’s website at ir.zailaboratory.com/webcasts-presentations and archived replay will be available for up to 30 days following the completion of the event.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212395139/en/

Investor Relations:
Christine Chiou / Lina Zhang
+1 (917) 886-6929 / +86 136 8257 6943
[email protected] / [email protected]

Media:
Shaun Maccoun / Xiaoyu Chen
+1 (857) 270-8854 / +86 185 0015 5011
[email protected] / [email protected]

Source: Zai Lab Limited

You May Also Be Interested In

• Uber Launches Baidu’s Fully Driverless Apollo Go in Dubai, Establishing the First Multi-Partner Autonomous Network Globally
• Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Development of AKIR001 for the Treatment of Solid Tumors
• Kytremavalk Reviews [UK]: How Does Kytremavalk Trading Platform Work?